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Abstract: We investigated whether diurnal differences in muscle force output are associated with
the post-translational state of muscle proteins. Ten physically active men (mean ± SD; age 26.7 ± 3.7 y)
performed experimental sessions in the morning (08:00 h) and evening (17:00 h), which were
counterbalanced in order of administration and separated by at least 72 h. Knee extensor maximal
voluntary isometric contraction (MVIC) force and peak rate of force development (RFD) were
measured, and samples of vastus lateralis were collected immediately after exercise. MVIC force
was greater in the evening (mean difference of 67 N, 10.2%; p < 0.05). Two-dimensional (2D)
gel analysis encompassed 122 proteoforms and discovered 6 significant (p < 0.05; false discovery
rate [FDR] = 10%) diurnal differences. Phosphopeptide analysis identified 1693 phosphopeptides
and detected 140 phosphopeptides from 104 proteins that were more (p < 0.05, FDR = 22%)
phosphorylated in the morning. Myomesin 2, muscle creatine kinase, and the C-terminus of titin
exhibited the most robust (FDR < 10%) diurnal differences. Exercise in the morning, compared to
the evening, coincided with a greater phosphorylation of M-band-associated proteins in human
muscle. These protein modifications may alter the M-band structure and disrupt force transmission,
thus potentially explaining the lower force output in the morning.
Keywords: maximum voluntary isometric contraction; muscle contraction; phosphopeptide;
phosphoproteomic; protein processing; post-translational; proteomics; rate-of-force development;
sarcomere; time of day
1. Introduction
The force output of muscle is a key component of athletic performance, and adequate levels of
muscle mass and function are critical to health and well-being in the general population [1]. For example,
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the power output of muscle becomes a key determinant of independence and quality of life in older
individuals [2]. The sarcomere is the basic contractile unit of muscle and consists of an ordered
arrangement of thick and thin myofilaments in a three-dimensional lattice. Sarcomeres are arranged in
series, bounded by Z-disks that connect with the muscle cytoskeleton, and have a central M-band that
connects the anti-parallel thick filaments at the center [3]. Myosin heavy-chain and filamentous actin are
the main proteins of the thick and thin filaments, respectively. In addition, the myofibrillar proteome
consists of numerous other major proteins, e.g., myosin light chains, troponins, and tropomyosins,
as well as lesser-known ancillary proteins whose functions remain enigmatic or are only recently
coming to light. Despite its highly ordered structure, striated muscle is renowned for its plasticity
and can adapt both quantitatively, through hypertrophy or atrophy, and qualitatively by changing
the relative proportion of myofibrillar protein isoforms. Remarkably, the maximum force that can
be produced by muscle varies throughout the day and is significantly greater in the evening than
the morning [4,5]. The difference in maximum isometric force between the morning and evening is
typically approximately 10% [6,7]. For context, this magnitude of difference is equivalent to the gain in
muscle force achieved after several weeks of resistance exercise training [8].
Time-of-day differences in maximal isometric force appear to be intrinsic to muscle rather
than secondary to fluctuations in neuromuscular drive [9] or body temperature [10]. In the last
decades, significant progress has been made in understanding the molecular workings of
the central (suprachiasmatic nucleus) and peripheral tissue clocks and their roles in biology [11].
At the molecular level, the circadian clock is a well-defined gene regulatory network composed of
transcriptional–translational feedback loops involving proteins such as circadian promotor output
cycles kaput (CLOCK) and brain and muscle ARNT like-1 (BMAL1; [12]). Early work in human
muscle [13] reported a diurnal difference in the expression of clock genes and the muscle linage gene,
myogenic factor 6. More detailed analysis of circadian gene expression in animals [14] identified further
muscle-specific genes, including myogenic differentiation protein 1 (MyoD), which exhibits a circadian
rhythm. The genetic deletion of key components of the molecular clock continues to be a powerful tool for
investigating cellular processes that are dependent on circadian regulation. Muscle-specific disruption
of the molecular clock results in impairments to glucose metabolism and insulin homeostasis [15]
in mice, and exercise at different times of day is associated with different metabolic responses in
muscle [16]. The deletion of BMAL1, whether from germline [17] or induced in adult muscle [18],
is associated with losses in muscle contractile force, which may be relevant to the diurnal differences in
maximum isometric force observed in humans. However, it is not yet clear how circadian oscillations
in gene expression affect hour-by-hour differences in the force output of muscle. The majority of
myofibrillar proteins have a half-life of approximately 30 days [19], so it is unlikely that changes in
gene expression and protein abundance account for diurnal differences in muscle force production.
Instead, the post-translational modification of proteins may be responsible. Modifications such as
phosphorylation can occur on second or minute timescales and are known to change the functional
properties of myofibrillar proteins [20].
Currently, fewer than 12 articles report analyses of human muscle biopsy samples in the context of
chronobiology. Moreover, a proteomic analysis of human muscle in the context of diurnal or circadian
rhythm has not yet been reported. Maximal contractions evoke acute changes in muscle protein
phosphorylation [21], but it is not yet clear whether an interaction exists between exercise and time of
day that could contribute to differences in the force output of muscle or the Zeitgeber effect of exercise
on muscle function. Therefore, we used proteomic techniques to investigate the post-translational
state of muscle proteins immediately after maximum force contractions in either the morning or
evening. Two-dimensional gel-electrophoresis (2DGE) is a useful ‘top–down’ proteomic method for
the non-targeted analysis of proteoforms. Proteoforms arise through specific combinatorial patterns of
post-translational modification and the splice-variation of protein isoforms. The post-translational
modification of specific myosin light chain isoforms alters the contractile properties of striated
muscle [22] and could contribute to time-of-day differences in maximal isometric force. Myosin light
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chain isoforms are readily resolved by 2DGE into proteoforms, which include the post-translational
modification of specific amino acid residues that can be identified using mass spectrometry [23].
In addition, the selective enrichment of modified proteins or peptides prior to mass spectrometry
is a well-established ‘bottom–up’ proteomic approach to studying post-translational modifications.
Often, bottom–up methods offer more comprehensive and higher throughput analysis than 2DGE;
however, the isolated analysis of site-specific modifications does not provide proteoform-specific
information [24]. Nevertheless, bottom–up analyses can be useful in identifying modifications to key
protein residues that may be associated with the difference in muscle force output between morning
and evening. Phosphorylation is perhaps the most widely studied post-translational modification.
Robust methods for the enrichment of phosphopeptides are established [25]; however, currently, fewer
than 6 articles report the phosphoproteome analysis of human skeletal muscle. The phosphoproteome
of human muscle has been mapped [26], and the acute response to endurance exercise has been
reported [27]. Herein, we investigate whether differences also exist in the muscle phosphoproteome
after exercise in the morning versus evening.
2. Materials and Methods
Pilot experiments recruited n = 20 males with age (mean ± SD): 26.0 ± 4.4 years; body mass:
75.1 ± 8.2 kg; height: 177.3 ± 6.8 cm; and normative retiring and rising times: 23:36 ± 0:36 h:min
and 06:24 ± 0:18 h:min, respectively. Verbal explanation of the experimental procedure was provided
to each individual, including the aims of the study, the possible risks associated with participation,
and the experimental procedures. Individuals provided written informed consent before participating
in the study. The experimental procedures were approved (14/WM/0065) by the National Research
Ethics Committee, UK and conformed to the standards set by the Declaration of Helsinki, except for
registration in a database.
Participants were selected if they met all the inclusion requirements, including habitual sleeping
duration of approximately 8 h per day, no reported sleep problems, did not routinely nap, had at least
2 years experience in strength or weight training, and habitually trained at any time of the day
during a typical week. Participants were also required to avoid alcohol 48 h prior to each test.
None of the participants had a history of bone fractures or musculoskeletal abnormalities, and none were
prescribed pharmacological treatment during the study. Participants were excluded from participating
if they had (i) recently (within the last 14 days) undertaken shift work or rapid travel across time zones;
(ii) declared health issues in the Physical Activity Readiness Questionnaire (PARQ); or (iii) had a mean
chronotype score <22 or >43 based on the Composite Morningness questionnaire (CMQ) [28]. The mean
chronotype score of the selected participants was intermediate (35.2 ± 4.5). Sleep Flexibility/Rigidity
[F/R] score 43.4 ± 5.6 and Languid/Vigour [L/V] score 43.4 ± 9.3. All experimental tests were conducted
in the United Kingdom between the months of March and May.
Each participant completed 5 familiarization sessions (which occurred between 12:00 and 13:00 h),
separated by 3-d intervals, to ensure full acquaintance with the experimental protocol. During each
familiarization session, participants performed maximal voluntary isometric contractions (MVIC)
of m. quadriceps femoris with electrical stimulation to assess the percentage activation (i.e., twitch
interpolation technique) and trials designed to measure the peak rate of force development (RFD) of
the same muscle. Thereafter, each participant completed a morning (07:30 h) and an evening (17:30 h)
experimental session (Figure 1) separated by 3 d and assigned in a randomized counter-balanced order.
Ten participants elected to undergo percutaneous needle biopsies, which were taken immediately after
RFD measurements. Participants retired at 23:00 h and woke at 06:00 h to be in the laboratories for
07:00 h. All sessions took place under standard laboratory conditions (lighting, room temperature,
and humidity = 200–250 lux, 19–20 ◦C, and 38–52%, respectively). Participants reported to the laboratory
in a fasted (≥7 h) state for the morning session and were instructed not to consume food for ≥4 h
prior to the evening session. Participants verbally stated they had complied with these restrictions on
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entry to the laboratory and recorded their dietary habits throughout the day including amount, type,
and timing of food and fluid intake.
At the beginning of each experimental session, participants inserted a rectal probe approximately
10 cm past their external anal sphincter (Grant, Squirrel, Cambridge, UK). Skin thermistors (Grant,
Cambridge, UK) were attached to four points of the body: sternum, upper arm (bicep mid-point),
thigh (quadriceps mid-point), and calf (mid-point). Recordings of skin temperature (Tsk) and rectal
temperature (Trec) were taken every minute for 30 min (data used for analysis were averaged over
the last 5 min), whilst participants remained awake in a semi-supine position. Muscle temperature (Tm)
was assessed in the vastus lateralis of the right leg using a needle thermistor (13050; ELAB, Rodovre,
Denmark). Trec, Tsk, and Tm were recorded after the active warm-up and after each MVIC and RFD
attempt. Participants self-rated their perceived effort (0–10 Likert scale; “0” representing no effort
and “10” maximal) after each MVIC and RFD exercise.
Measurements of quadriceps femoris maximum voluntary isometric contraction (MVIC) force
and peak RFD of the right leg were conducted using an isometric chair (Lido Active, Loredan, Davis,
CA, USA). The position of the subject in the chair was standardized in accordance with the guidelines
set by the manufacturer, and the hips and knee were secured at an angle of 90◦ with inextensible straps.
MVIC was conducted with and without the interpolated twitch technique (ITT) to accustom participants
to producing and maintaining MVIC force over the required (4 s) duration. For ITT contractions,
the quadriceps femoris was electrically stimulated using two surface electrodes (7 × 12.7 cm Dura-stick
II, Chattanooga Group, Hixson, TN, USA,), which were positioned on the anterolateral side of the thigh,
on the belly of the rectus femoris and vastus lateralis muscles. An initial familiarization session was
used to obtain maximal current (mA) tolerance and establish the supra-maximal current amplitude for
superimposition during MVIC. Under resting conditions, the amperage of a 240 V square-wave pulse
(100 µs, 1 Hz; Digimeter, DS7, Hertfordshire, UK) was progressively increased until further increases
in intensity caused no further gain in twitch force [29]. Familiarization sessions were conducted until
MVIC and RFD values reached a plateau, and the average voluntary muscle activation during the ITT
was greater than 80%. N.B. ITT was used solely to determine the voluntary activation capacity and not
to estimate the force of a maximally activated muscle. Force data were acquired (200 Hz) using a force
transducer (KAP, Bienfait B.V. Haarlem, The Netherlands) and analyzed with commercially available
software (AcqKnowledge III; Biopac Systems Inc, Aero Camino Goleta, CA, USA), which is consistent
with previous work [10].
To measure quadriceps femoris peak RFD, participants performed maximum velocity contractions
as forcefully as possible without countermovement. Visual data presentation was used to provide
real-time ‘biofeedback’ and ensure no countermovement preceded each kick. Ten kicks were performed
interspersed by 30 s rest periods (Figure 1). The peak RFD was defined as the highest positive value
from the first derivative of the force signal (i.e., the greatest slope of the force–time curve). The 3 efforts
of greatest force and no discernible counter-movement were selected for analysis [30].
A subset of 10 participants underwent a percutaneous needle biopsy of their right quadriceps
(vastus lateralis) that was completed within 5 min of cessation of the muscle contraction protocol
(Figure 1). Biopsies were performed under local anaesthesia (0.5% Marcaine) using a Bard Monopty
12-gauge × 10 cm length disposable core biopsy instrument (Bard Biopsy System, Tempe, AZ, USA).
A 10 mm longitudinal stab incision was made, and the muscle fascia was pierced to enable the biopsy
needle to be passed through the incision. Muscle samples (approximately 40 mg) were immediately
frozen in liquid nitrogen and stored at −80 ◦C until further analysis.
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Figure 1. Experimental protocol. Schematic diagram of the experimental protocol undertaken by participants in the morning (07:30 h) and evening (17:30 h)
interspersed by a 72-h wash-out period. Temperature data were collected from the rectum, muscle, and skin after a 30 min acclimatization period (baseline), after a cycle
ergometry warm up (5 min at 150 W) and after periods of data collection, including the measurement of quadriceps maximal voluntary isometric contraction (MVIC)
force and peak rate of force development (RFD). Participants performed 5 blocks of MVIC (dark bars) consisting of 1 unstimulated and 3 stimulated contractions,
which were interspersed by rest periods (light bars). The peak RFD of the quadriceps muscle was assessed by 10 attempts (dark bars) interspersed by 30 s recovery
periods. Samples of vastus lateralis muscle were taken by percutaneous needle biopsy immediately after RFD measurements.
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Muscle samples were ground under liquid nitrogen using a pestle and mortar. Muscle powders
were accurately weighed and homogenized on ice in 10 volumes of 1% (v/v) Triton X-100, 40 mM Tris
pH 7.4, including PhosSTOPTM phosphatase inhibitor and cOmpleteTM protease inhibitor cocktail
(Roche, Indianapolis, USA) using a glass–Teflon homogenizer. Homogenates were centrifuged at
1000× g, 4 ◦C for 5 min and supernatants containing soluble proteins were decanted and stored on ice.
The pellet, which contains the majority of myofibrillar proteins, was resuspended in homogenization
buffer and centrifuged at 1000× g, 4 ◦C for 5 min. The washed myofibrillar pellet was solubilized in
Lysis buffer (7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 30 mM Tris pH 8.5) and cleared by centrifugation
at 12,000× g, 4 ◦C for 45 min. The protein concentrations of each myofibrillar and soluble protein
fraction were measured using the Bradford assay (Sigma-Aldrich, Poole, Dorset, UK), and samples
were normalized to 5 µg/µL in Lysis buffer.
Top–down analysis of muscle protein modifications was performed by 2DGE as described
previously [31]. Myofibrillar samples were resolved on immobilized pH gradient (IPG) strips
(GE Healthcare, Little Chalfont, UK) by isoelectric focusing. The protein load was 250 µg and 50 µg
per gel for broad-range (pH 3–11) and narrow-range (pH 4–7) gels, respectively. Second-dimension
denaturing electrophoresis was performed through linear 11% poly-acrylamide gels. Proteins were
stained with colloidal Coomassie blue (Bio-Rad Laboratories, Hercules, CA, USA). Digitized gel images
(600 dpi, 16-bit grayscale) of samples taken from each participant in morning and evening conditions
(n = 10 participants; total of 20 gels) were normalized by an inter-sample abundance ratio calculated
from ‘non-changing’ features and between group differences were analyzed using SameSpots (TotalLab,
Newcastle upon Tyne, UK), which is consistent with previous work [32].
Proteins were identified by reverse-phase liquid chromatography (LC)–electrospray ionization
(ESI)–tandem mass spectrometry (MS/MS) of tryptic digests, as reported in [33]. Briefly, gel spots
were excised from analytical gels (n = 20 biological replicates) or preparative gels of pooled samples
and tryptic in-gel digestion was performed using an Xcise robot (Proteome Systems, North Ryde,
Australia). LC-ESI-MS/MS was performed using a quadrupole-high capacity ion-trap mass spectrometer
(HCT Ultra ETD II; Bruker Daltonics, Billerica, MA, USA) coupled via an ESI source to a nano-flow
LC system (Ultimate 3000; Thermo Scientific, Waltham, MA, USA). Data-dependent MS/MS analysis
in alternating collision-induced dissociation (CID) and electron-transfer dissociation (ETD) modes
was performed, selecting the two most abundant precursor ions with active exclusion (30 s) enabled.
Raw data were processed (Data Analysis 4.0, Bruker Daltonics, Billerica, MA, USA) and error tolerant
searches of Mascot generic format files were performed against the UniProt database, which was
restricted to Human using a locally implemented Mascot (www.matrixscience.com) server (version
2.2.03). The enzyme specificity was trypsin allowing 1 missed cleavage, carbamidomethyl modification
of cysteine (fixed), oxidation of methionine (variable), and an m/z error of ± 0.5 Da.
The tryptic digestion of soluble muscle proteins was performed using the filter-aided sample
preparation (FASP) method. Aliquots containing 400 µg protein were washed with 200 µL of UA
buffer (8 M urea, 100 mM Tris, pH 8.5). Proteins were incubated at 37 ◦C for 15 min in UA buffer
containing 100 mM dithiothreitol followed by incubation (20 min at 4 ◦C) protected from light in UA
buffer containing 50 mM iodoacetamide. UA buffer was exchanged for 50 mM ammonium bicarbonate,
and sequencing-grade trypsin (Promega, Madison, WI, USA) was added at an enzyme to protein
ratio of 1:50. Digestion was allowed to proceed at 37 ◦C overnight; then, peptides were collected in
100 µL 50 mM ammonium bicarbonate containing 0.2% trifluoroacetic acid. Peptide solutions were
desalted using disposable Toptip C18 spin columns (Glygen Corp., Columbia, MD, USA) and vacuum
centrifuged to dryness. Phosphopeptides were selectively enriched by binding to titanium dioxide
(TiO2)-spin tips (Pierce), which was consistent with previous work [34]. Enriched phosphopeptide
solutions were immediately adjusted to pH 4 with formic acid, vacuum centrifuged to dryness, and then
resuspended in 0.1% formic acid (FA)prior to LC-ESI-MS/MS analysis.
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The LC-ESI-MS/MS analysis of phosphopeptide-enriched samples was performed using an
Ultimate 3000 RSLCTM nano system (Thermo Scientific, Waltham, MA, USA) coupled to a QExactiveTM
mass spectrometer (Thermo Scientific, Waltham, MA, USA). Samples (5 µL each) were loaded by
partial loop injection onto the trapping column (Thermo Scientific, PepMap100, C18, 75 µm × 20 mm)
at a flow rate of 4 µL/min with 0.1% (v/v) trifluoroacetic acid (TFA) for 7 min. Samples were resolved
on the analytical column (Easy-Spray C18 75 µm × 500 mm 2 µm column) using a gradient of 97%
A (0.1% FA) 3% B (99.9% ACN 0.1% FA) to 60% A 40% B over 90 min at a flow rate of 300 nL/min.
The data-dependent program used for data acquisition consisted of a 70,000 resolution full-scan MS
scan (AGC set to 106 ions with a maximum fill time of 250 ms); the 10 most abundant peaks were
selected for MS/MS using a 17,000 resolution scan (AGC set to 5 × 104 ions with a maximum fill time
of 250 ms) with an ion selection window of 3 m/z and a normalized collision energy of 30. To avoid
the repeated selection of peptides, the MS/MS program used a 30 s dynamic exclusion window.
MS spectra were aligned using the Progenesis QI for Proteomics (Nonlinear Dynamics, Newcastle,
UK). Prominent ion features were used as vectors to match each dataset to a common reference
chromatogram. An analysis window of 9–99 min and 200–2000 m/z was selected encompassing charge
states of ≤8. Peak lists were searched against the UniProt database and restricted to Human using a
locally implemented Mascot (www.matrixscience.com) server (version 2.2.03). The enzyme specificity
was trypsin, allowing one missed cleavage, fixed carbamidomethyl of cysteine, and variable oxidation
of methionine and phosphorylation of serine (S), threonine (T), and tyrosine (Y). The instrument
type was ESI-FTICR, and mass tolerances were 10 ppm for peptides and 0.01 Da for fragment ions.
The Mascot output (xml format), which was restricted to non-homologous protein identifications
(false discovery rate < 1%), was recombined with MS profile data in Progenesis QI for Proteomics,
and peptide abundance data were normalized by the inter-sample abundance ratio calculated from
‘non-changing’ features. Peptide features with molecular weight search score (MOWSE) scores below
the identity threshold (Mud-PIT scoring) were excluded.
Data were analyzed in R version 3.5.2 and are presented as mean and standard deviation (SD)
unless otherwise stated. Morning and evening MVIC force and peak RFD were compared with
paired t-tests. Statistical analysis of proteomic data was conducted by within-subject one-way analysis
of variance. Log transformed spot volumes or MS peptide data were normalized by inter-sample
abundance ratio and used to investigate within-subject differences between morning and evening
conditions. To determine the false discovery rate (FDR), p-value distributions were used to calculate
q-values [35]. Functional annotation of proteomic data was conducted using the Search Tool for
the Retrieval of Interacting Genes/Proteins [STRING; [36].
3. Results
3.1. Reliability and Diurnal Variation Data: MVIC, % Activation, RFD, and Subjects Rated Maximal Effort in
n = 20 Subjects
The intra-class correlation coefficient between MVIC force during the 4th and 5th familiarization
sessions was 0.96 (95% CI, 0.91–0.99). MVIC force in the evening was 10.2% greater than in the morning
(721 ± 80 versus 654 ± 79 N, p = 0.00854; Figure 2A). The intra-class correlation coefficient between
peak RFD data collected during the 4th and 5th familiarization sessions was 0.45 (95% CI, 0.03–0.74).
Peak RFD in the evening was 18% greater (7052 ± 1261 versus 5972 ± 1501 N/s, p = 0.0199; Figure 2B)
than in the morning. The level of voluntary activation in the morning 82.8 ± 7.8% did not differ
(p = 0.061) from the evening 86.5 ± 6.4%, and there were no significant difference in the rating of
perceived effort. In all cases, participants rated 10/10 for effort regardless of whether the session was
conducted in the morning or evening.
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muscle biopsy samples, whereas open (white) data points represent data from n = 10 participants that
did not undergo biopsy procedures. Within-subject data are connected by dashed lines and group
data (median, quartile ranges) are summarized by ‘box and whisker’ plots. Statistical differences were
assessed by Student’s paired t-test, n = 20.
3.2. Data Handling: 10 Subjects from the Cohort of 20 Volunteered for Muscle Biopsy Procedures; Hence,
Only Their Data (Temperature, MVIC, and RFD) Are Reported below to Align with the Proteomic Analyses
3.2.1. Resting Rectal, Skin, and Muscle Temperatures (n = 10)
At rest, Trec was greater in the evening (mean difference = 0.50 ◦C, p = 0.001, 95% CI: 0.27–0.74 ◦C)
than morning (Figure 3A). Tm exhibited a similar diurnal variation (mean difference = 0.69 ◦C,
p = 0.019, 95% CI: 0.14–1.23 ◦C; Figure 3B), wh reas, Tsk xhibited no significant diurnal variation
(mean difference = 0.26 ◦C, p = 0.377; Figure 3C). No significant interactions were found between
temperature responses and time of day. The profiles of the temperature measurements (Trec, Tm,
and Tsk) rose and fell in parallel over the three time points in both morning and evening conditions.
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muscle temperature (B), and skin temperature (C), were recorded during the last 5 min of baseline
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or peak rate of force development (RFD) protocols. Data are presented as mean, standard deviation
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3.2.2. MVIC, % Activation, Peak RFD, and Subject-Rated Maximal Effort (n = 10)
MVIC force in the evening was 9.2% greater (738 ± 98 versus 676 ± 92 N, p = 0.007) than in
the morning (Figure 2A, closed/shaded data points). Peak RFD (7364 ± 1440 versus 6514 ± 1724 N/s,
p = 0.064) was 13% greater in the evening (Figure 2B, closed/shaded data points). The level of voluntary
activation for MVIC in the morning 79.6% did not differ (p = 0.056) from the evening 85.2%, and there
were no significant differences in the rating of perceived effort.
3.2.3. Proteomic Data
The analysis of human myofibrillar proteins by narrow range (pH 4–7) 2DGE (Figure 4 insets) was
used to investigate differences in the relative abundance of proteoforms of essential and regulatory
myosin light chains. Essential myosin light chains (MYLC1/3) were resolved as 4 proteoforms,
slow-twitch/ventricular regulatory myosin light chains (MLRV) were resolved as 3 proteoforms,
and fast-twitch/skeletal muscle myosin regulatory light chains (MLRS) were resolved as 4 proteoforms.
There were no statistically significant differences in myosin light chain proteoform abundance between
morning and evening conditions (Table 1).
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Table 1. Myosin light chain proteoform abundances.
UniProt ID Description Spot # Morning Evening p
MYL1/3 Essential myosin light chain 1/3 1 924 (498) 785 (612) 0.727
2 4426 (1504) 3968 (1984) 0.884
3 10,942 (3173) 9788 (4894) 0.485
4 2378 (808) 2192 (1293) 0.431
MLRV Regulatory myosin light chain, slow/ventricular 5 2675 (1524) 2985 (2179) 0.498
6 4176 (1837) 3699 (2182) 0.459
7 1940 (950) 1600 (10,089) 0.389
MLRS Regulatory myosin light chain, fast/skeletal 8 1557 (1027) 2206 (1875) 0.216
9 4675 (1589) 5214 (3128) 0.151
10 4420 (1149) 3762 (1768) 0.467
11 1286 (540) 982 (569) 0.426
HSPB6 Heat shock protein 20 12 282 (214) 0.00 (0.00) -
Spot # correspond with the 2D gel map (Figure 5 inset a). UniProt identifier and protein description based on
peptide mass spectrometry of in-gel protein digests. Normalized spot abundances (AU) in the morning and evening
are presented as mean (SD) and statistical difference (p) was determined by within-subject ANOVA (n = 10).
A broader range (pH 3–11) of 2DGE resolved 122 protein spots (Figure 4 and Table 2). In total,
40 non-redundant proteins were identified, i.e., the majority of proteins were detected in multiple gel
spots that represent different proteoforms. The abundance of 6 proteoforms was statistically (p < 0.05)
different between morning and evening conditions (Table 2). In the evening, greater abundances were
observed in myosin binding protein C1 (80%), glycogen phosphorylase (43%), and beta enolase (24%),
whereas the abundances of myosin binding protein H (−18%), nebulin (−48%), and troponin T slow
(−22%) were less in the evening compared to the morning. The greatest difference was in the abundance
of the slow isoform of myosin binding protein C (MYBPC1), which was resolved as a series of 6
proteoforms. Therefore, the difference in abundance of spot # 164 reported here may represent a change
in post-translational modification. LC-ESI-MS/MS analysis of all MYBPC1 proteoforms (spot numbers:
150, 153, 158, 163, 164, and 165) did not unambiguously identify site-specific modifications that were
unique to a particular MYBPC1 proteoform. The phosphorylation of MYBPC1 S178 was detected in two
MYBPC1 proteoforms (spots 153 and 158), and therefore, it was not specifically related to time-of-day
differences in the pattern of MYBPC1 proteoforms.
The label-free quantitation of TiO2-enriched human muscle peptides profiled 1693
phosphopeptides (721 proteins) in n = 9 paired samples (1 sample was lost during processing)
taken in the morning and evening condition. Generally, the abundance of muscle phosphopeptides was
greater in the morning than evening (Figure 5A). One-hundred and forty phosphopeptides from 104
proteins were statistically different (p < 0.05) at a false discovery rate (FDR) of 22% (Figure 5A), and 7
peptides had a false discovery rate of <10% (Figure 5B). Of 141 peptides at p < 0.05, 131 are reported in
PhosphositePlus® (https://www.phosphosite.org), 122 have high throughput (HTP) associated papers
with PubMed identifiers (PMID), 46 had low throughput (LHP) PMID associated papers, and 10 were
new or have not been reported previously. Phosphopeptide abundance data including literature links
are available online at 10.6084/m9.figshare.10316624 (Supplementary Material). Network analysis of
104 significant proteins using STRING (Figure 6) highlighted clusters including (i) myofibrillar proteins
centering around titin and myomesin; (ii) apoptosis-related proteins centering around caspase; and (iii)
redox proteins including glutathione transferase and peroxiredoxin 2.
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Table 2. Diurnal differences in myofibrillar proteoform abundance.
Spot # UniProt ID Protein Name MOWSE % Seq Anova (p) FC Morning Mean Morning SD Evening Mean Evening SD
335 PYGM Glycogen phosphorylase, muscle form 1938 53 0.0155 1.43 245 44 350 104
163 MYPC1 Myosin-binding protein C, slow-type 2135 42 0.0226 1.80 343 86 617 357
703 MYBPH Myosin-binding protein H 425 23 0.0313 1.17 133 28 114 26
874 ENOB Beta-enolase 1040 55 0.0335 1.24 814 199 1007 174
1046 TNNT1 Troponin T, slow skeletal muscle 738 32 0.0433 1.22 239 71 196 45
154 NEBU Nebulin 964 6 0.0435 1.48 959 352 648 252
391 MYH2 Myosin-2 1510 18 0.0546 1.37 239 56 329 158
881 KCRM Creatine kinase M-type 922 54 0.0570 1.17 535 74 625 118
795 ACTS Actin, alpha skeletal muscle 1011 54 0.0620 1.47 271 114 185 56
742 ACTN2 Alpha-actinin-2 80 4 0.0727 1.25 510 102 408 134
1059 TNNT3 Troponin T, fast skeletal muscle 394 24 0.0735 1.32 244 84 186 54
992 ALDOA Fructose-bisphosphate aldolase A 733 58 0.0929 1.19 472 126 559 138
903 ACTS Actin, alpha skeletal muscle 1009 62 0.0931 1.67 16,872 10,694 10,109 2314
135 MYPC2 Myosin-binding protein C, fast-type 2015 45 0.0978 1.23 168 54 137 41
1357 KCRM Creatine kinase M-type 466 32 0.0978 1.43 2542 1135 1782 577
686 NEBU Nebulin 2181 13 0.1017 1.17 336 66 394 69
386 MYH2 Myosin-2 1266 13 0.1048 1.27 233 78 295 104
739 DESM Desmin 1884 63 0.1072 1.20 1176 181 979 292
1043 TNNT1 Troponin T, slow skeletal muscle 599 33 0.1143 1.28 884 293 689 278
596 MYH7 Myosin-7 1229 17 0.1321 1.15 259 66 298 49
392 MYH2 Myosin-2 709 12 0.1328 1.17 109 44 128 36
390 MYH2 Myosin-2 1367 14 0.1481 1.28 177 40 227 89
855 ACTS Actin, alpha skeletal muscle 1319 65 0.1531 1.25 18,032 6216 14,461 4631
158 MYPC1 Myosin-binding protein C, slow-type 2460 49 0.1606 1.32 547 224 721 297
387 MYH2 Myosin-2 915 12 0.1636 1.24 173 85 214 71
685 KPYM Pyruvate kinase isozymes M1/M2 1329 51 0.1662 1.17 398 68 466 112
731 DESM Desmin 2161 72 0.1818 1.16 2919 408 2527 728
153 MYPC1 Myosin-binding protein C, slow-type 2648 51 0.1857 1.34 518 218 694 314
344 PYGM Glycogen phosphorylase, muscle form 1560 43 0.1876 1.53 198 48 304 242
741 DESM Desmin 1927 67 0.1927 1.17 3290 778 2811 997
544 ALBU Serum albumin 1539 56 0.2047 1.25 682 203 852 348
389 TNNT1 Troponin T, slow skeletal muscle 153 23 0.2070 1.16 558 103 645 155
1065 TNNT3 Troponin T, fast skeletal muscle 421 26 0.2103 1.18 542 124 460 117
164 MYPC1 Myosin-binding protein C, slow-type 2581 51 0.2105 1.25 337 57 423 190
751 TBA4A Tubulin alpha-4A 467 29 0.2232 1.14 312 60 274 43
997 ALDOA Fructose-bisphosphate aldolase A 812 60 0.2234 1.21 652 188 789 289
546 ALBU Serum albumin 1622 59 0.2244 1.34 1381 468 1850 766
812 ATPA ATP synthase subunit alpha, mitochondrial 1275 45 0.2274 1.15 688 164 790 219
150 MYPC1 Myosin-binding protein C, slow-type 2849 50 0.2300 1.30 442 236 575 280
813 ATPA ATP synthase subunit alpha, mitochondrial 963 42 0.2328 1.10 755 167 829 176
1606 VIME Vimentin 1861 69 0.2342 1.35 707 339 955 389
1105 TPM2 Tropomyosin beta chain 567 32 0.2501 1.19 454 120 381 80
1251 CAH3 Carbonic anhydrase 3 419 44 0.2622 1.14 829 240 944 230
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Table 2. Cont.
Spot # UniProt ID Protein Name MOWSE % Seq Anova (p) FC Morning Mean Morning SD Evening Mean Evening SD
878 ENOB Beta-enolase 1196 53 0.2624 1.19 1109 283 1325 358
616 CATA Catalase 710 38 0.2974 1.77 832 103 1476 1963
941 KCRM Creatine kinase M-type 890 54 0.3013 1.14 1295 299 1480 439
947 KCRM Creatine kinase M-type 1295 57 0.3075 1.14 6801 1461 7786 1689
1057 ACTC Actin, alpha cardiac muscle 1 52 11 0.3596 1.16 329 118 383 185
505 HSP7C Heat shock cognate 71 kDa protein 1246 39 0.3731 1.19 1386 475 1643 850
500 HSP71 Heat shock 70 kDa protein 1A/1B 1470 46 0.3816 1.02 583 99 570 136
1085 TPM3 Tropomyosin alpha-3 chain 1478 72 0.3846 1.10 37,171 11,538 33,691 9083
1603 ALBU Serum albumin 1625 58 0.3869 1.22 714 404 867 335
1097 TNNT1 Troponin T, slow skeletal muscle 576 32 0.3914 1.20 1448 656 1207 609
553 ALBU Serum albumin 1838 60 0.3938 1.29 4881 2765 6293 3338
902 ACTS Actin, alpha skeletal muscle 962 63 0.4326 1.25 8992 5539 7196 2076
1374 MYL3 Myosin light chain 3 856 77 0.4537 1.10 8098 3473 7382 2866
1078 MYOZ1 Myozenin-1 848 85 0.4556 1.00 401 76 402 239
1336 TPIS Triosephosphate isomerase 929 76 0.4585 1.04 316 48 304 100
1103 KCRM Creatine kinase M-type 418 29 0.4598 1.40 623 607 446 123
944 KCRM Creatine kinase M-type 1100 53 0.4644 1.12 3853 690 4310 1195
900 ACTS Actin, alpha skeletal muscle 415 39 0.4649 1.21 3869 2169 3198 713
1272 MYOZ1 Myozenin-1 154 29 0.4785 1.05 355 88 373 47
532 PGM1 Phosphoglucomutase-1 876 37 0.4889 1.09 446 125 409 80
106 MYH2 Myosin-2 3726 33 0.4924 1.59 550 340 874 888
1090 TNNT3 Troponin T, fast skeletal muscle 520 32 0.5034 1.12 591 178 528 89
333 PYGM Glycogen phosphorylase, muscle form 1611 47 0.5039 1.21 164 33 198 95
1503 KCRM Creatine kinase M-type 151 13 0.5085 1.06 1063 345 1007 590
1032 TNNT3 Troponin T, fast skeletal muscle 491 27 0.5192 1.23 1032 534 837 258
943 KCRM Creatine kinase M-type 1126 59 0.5267 1.06 2690 574 2846 551
1056 TNNT1 Troponin T, slow skeletal muscle 687 37 0.5340 1.13 8515 4319 7506 4221
1049 TNNT1 Troponin T, slow skeletal muscle 652 36 0.5550 1.10 1792 601 1630 818
165 MYPC1 Myosin-binding protein C, slow-type 2366 51 0.5618 1.14 323 69 368 161
1266 TPIS Triosephosphate isomerase 932 65 0.5624 1.07 1389 280 1489 354
1132 MYH2 Myosin-2 616 8 0.5679 1.05 1154 324 1209 255
604 MYH2 Myosin-2 1104 13 0.5805 1.05 199 43 189 41
121 MYH2 Myosin-2 4044 37 0.5910 1.51 691 599 1041 1196
455 KPYM Pyruvate kinase isozymes M1/M2 815 36 0.6060 1.06 856 158 810 117
550 ALBU Serum albumin 1852 65 0.6109 1.23 2514 1360 3093 1897
1074 G3P Glyceraldehyde-3-phosphatedehydrogenase 1068 54 0.6170 1.03 3635 771 3532 1105
925 ACTS Actin, alpha skeletal muscle 1277 63 0.6537 1.05 73,798 17,469 77,544 17,257
123 MYH2 Myosin-2 3325 34 0.6580 1.31 819 851 1072 1290
798 ATPB ATP synthase subunit beta, mitochondrial 1882 68 0.6678 1.13 947 356 1069 547
1083 TNNT3 Troponin T, fast skeletal muscle 583 34 0.6867 1.12 2406 775 2689 1066
136 MYPC2 Myosin-binding protein C, fast-type 1838 41 0.6868 1.07 223 72 207 45
1073 TNNT3 Troponin T, fast skeletal muscle 482 26 0.6887 1.09 1620 579 1492 603
1048 TNNT1 Troponin T, slow skeletal muscle 738 32 0.6912 1.25 3355 2869 2681 1052
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Table 2. Cont.
Spot # UniProt ID Protein Name MOWSE % Seq Anova (p) FC Morning Mean Morning SD Evening Mean Evening SD
471 MYH2 Myosin-2 1204 15 0.6940 1.09 202 91 186 98
934 KCRM Creatine kinase M-type 1134 54 0.6981 1.03 1253 233 1222 210
1115 MYOZ1 Myozenin-1 378 30 0.7011 1.05 1462 416 1393 415
904 ACTS Actin, alpha skeletal muscle 877 55 0.7143 1.01 9431 1361 9383 3034
443 MYH2 Myosin-2 978 13 0.7267 1.05 331 103 348 96
1381 KCRM Creatine kinase M-type 469 28 0.7267 1.08 24,048 9478 22,334 6612
115 MYH7 Myosin-7 4288 35 0.7551 1.14 2646 2960 3028 3141
1061 TNNT3 Troponin T, fast skeletal muscle 457 36 0.7595 1.28 540 382 424 155
1044 ACTC Actin, alpha cardiac muscle 1 342 28 0.7668 1.14 2912 1480 2552 917
1080 ACTC Actin, alpha cardiac muscle 1 183 23 0.7707 1.06 4741 1932 4479 2310
270 ACTN2 Alpha-actinin-2 3558 69 0.7779 1.08 2145 422 2326 812
271 ACTN2 Alpha-actinin-2 3354 71 0.7866 1.04 679 243 706 256
274 ACTN2 Alpha-actinin-2 3445 69 0.7899 1.07 1058 239 1128 390
187 MYH7 Myosin-7 3534 31 0.7939 1.55 6318 8061 4082 3064
1051 TNNT3 Troponin T, fast skeletal muscle 507 36 0.8007 1.11 1454 657 1312 446
1108 MYOZ1 Myozenin-1 708 50 0.8010 1.02 3435 1569 3513 1097
332 PYGM Glycogen phosphorylase, muscle form 1651 44 0.8203 1.01 295 50 299 93
330 TPM1 Tropomyosin alpha-1 chain 947 47 0.8216 1.07 1964 874 1834 716
1100 TNNT3 Troponin T, fast skeletal muscle 474 37 0.8243 1.12 4641 2707 4144 1391
1095 TNNT3 Troponin T, fast skeletal muscle 452 28 0.8373 1.09 1477 719 1355 374
499 HSP71 Heat shock 70 kDa protein 1A/1B 1070 39 0.8419 1.02 516 114 508 118
980 TNNT1 Troponin T, slow skeletal muscle 696 35 0.8427 1.01 1131 271 1146 265
1198 LDB3 LIM domain-binding protein 3 609 17 0.8445 1.01 2437 827 2415 1038
899 DESM Desmin 198 11 0.8495 1.08 1329 574 1230 235
1129 VDAC1 Voltage-dependent anion-selective channelprotein 1 612 59 0.8774 1.10 383 206 347 82
1552 HERC1 Probable E3 ubiquitin-protein ligase HERC1 52 2 0.8852 1.06 1557 547 1652 1207
1101 TNNT3 Troponin T, fast skeletal muscle 540 33 0.9155 1.01 1068 440 1077 383
477 MYH2 Myosin-2 2036 26 0.9173 1.08 564 398 609 497
533 MYH2 Myosin-2 1084 13 0.9250 1.27 365 409 289 165
1397 ENOB Beta-enolase 266 26 0.9287 1.02 12,335 3415 12,540 3761
535 MYH2 Myosin-2 1195 17 0.9394 1.23 456 482 370 163
1451 TNNI2 Troponin I, fast skeletal muscle 378 50 0.9545 1.02 229 127 225 130
479 MYH2 Myosin-2 1359 18 0.9612 1.04 543 385 563 481
275 ACTN2 Alpha-actinin-2 3512 71 0.9648 1.04 925 221 965 355
534 MYH2 Myosin-2 1360 16 0.9683 1.14 588 587 515 327
336 PYGM Glycogen phosphorylase, muscle form 1778 50 0.9720 1.02 310 96 305 69
1251 HBB Hemoglobin subunit beta 441 60 0.9780 1.00 834 137 837 171
195 MYH7 Myosin-7 4307 32 0.9894 1.34 2446 3633 1821 1188
1060 TNNT3 Troponin T, fast skeletal muscle 481 26 0.9915 1.01 2012 749 2001 801
1034 TPM2 Tropomyosin beta chain 1450 69 0.9963 1.01 22,483 6641 22,339 5236
Spot # correspond with the 2D gel map (Figure 4). UniProt identifier and protein name based on peptide mass spectrometry of in-gel protein digests searched against human entries in
the SwissProt database using Mascot. The probability-based molecular weight search score (MOWSE) and percentage of protein sequence identified are presented. Spot abundances (AU)
in the morning and evening are presented as mean (SD) and statistical difference (P) was determined by within-subject ANOVA (n = 10). Fold change (FC) is spot abundance in the evening
compared to the morning condition.
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We report widespread differences in the post-translational state of human muscle proteins after 
exercise in the morning (08:00 h) and evening (18:00 h). In particular, our data indicate differences in 
the phosphorylation of proteins within or close to the muscle M-band that could relate to the well-
established morning versus evening differences in muscle isometric force. Our novel analysis also 
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Figure 6. Network of phosphorylat Network of known and predicted interactions
between proteins (n = 141) with phos t at exhibited statistically significant (p < 0.05)
differences in phosphorylation betwe n morning and evening co ditions. The etwork was constructed
using he Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and subsets of
proteins were highlight d by k-means clustering (6 groups). Node annotati ns repr sent gene
names and phosphorylation sites. The width of the vectors indicate levels of evidence for protein
interconnections (e.g., interaction, co-expression, or biblio etric data). Group 1 (orange) contains
proteins associated with the myofibrillar apparatus and muscle cytoskeleton. Group 2 (red) is
characterized by proteins involved in apoptosis (e.g., caspase 3, CASP3). Group 1 and 2 are
interconnected by myc box-dependent-interacting protein 1 (BIN1; blue) which may be a key component
of the muscle M-Band in addition to its role associated with t-tubules. Smaller groups are characterized
by calcium-handling proteins (purple) or redox enzymes (green).
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4. Discussion
We report widespread differences in the post-translational state of human muscle proteins
after exercise in the morning (08:00 h) and evening (18:00 h). In particular, our data indicate
differences in the phosphorylation of proteins within or close to the muscle M-band that could relate to
the well-established morning versus evening differences in muscle isometric force. Our novel analysis
also adds to emerging evidence regarding the daily timing of exercise and the use of exercise as a
Zeitgeber for optimal muscle function [37]. The current investigation was limited to the interaction
between exercise and time of day; therefore, further work is required to investigate the main effects of
exercise or time of day in isolation. For example, it will be important to resolve which of the differences
in protein post-translational modification are intrinsic diurnal differences and occur in the absence of
the exercise stimulus.
The unsupervised network analysis of proteins that contained significant time-of-day differences
in phosphorylation status (Figure 6) highlighted a cluster of myofibrillar proteins, including prominent
links between titin (TTN) and myomesin 2 (MYOM2). TTN and MYOM2 were also amongst the most
highly significant (p < 0.05, FDR < 10%) differences (Figure 5B) alongside muscle creatine kinase
(KCRM), heat shock 90 proteins (HS90A and HS90B), and the mitochondrial importer receptor subunit
(TOM70). With the exception of TOM70, a commonality shared amongst these proteins is their
involvement in, or localization to, the sarcomeric M-band (Figure 7).
Proteomes 2020, 8, x FOR PEER REVIEW 15 of 22 
 
between exercise and time of day; therefore, further work is required to investigate the main effects 
of exercise or time of day in isolation. For example, it will be important to resolve w ich of the 
differenc s in protein post-translational modification are intrinsic diurnal differences and occur in 
the absence of the exercise stimulus. 
The unsupervised network analysis of proteins that contained signif cant time-of-day 
differenc s in phosphorylation status (Figure 6) highlighted a cluster of myofibrillar proteins, 
including prominent links between titin (TTN) and myomesin 2 (MYOM2). TTN and MYOM2 were 
also amongst the most highly significant (p < 0.05, FDR < 10%) differences (Figure 5B) alongside 
muscle creatine kinase (KCRM), heat shock 90 proteins (HS90A and HS90B), and the mitochondrial 
importer receptor subunit (TOM70). With the exception of TOM70, a commonality shared amongst 
these proteins is their involvement in, or localization to, the sarcomeric M-band (Figure 7). 
 
Figure 7. Diurnal differences in M-band phosphorylation. Diagrammatic representation of M-band 
protein interactions redrawn from [38]. Myomesin 1 (MYOM1) and obscurin (OBSCN) are principal 
M-band proteins [39]. The N-terminal regions of MYOM1 interact with myosin heavy chain (MYH), 
titin (TTN), and muscle creatine kinase (KCRM), whereas the C-terminal regions of MYOM1 dimerize 
in an anti-parallel arrangement that corresponds with the M-bridges [40]. MYOM1 interacts with the 
C-terminal regions of TTN within the M-band. The TTN kinase domain (resides 32,178–32,432) 
includes the regulatory Y32341 residue [41], whereas we discovered that the phosphorylation of S33624 of 
TTN is greater in the morning than evening. Myomesin 2 (MYOM2, formally known as M-Protein) 
interacts with the light meromyosin (LMM) region of MYH and the C-terminal region of TTN [42]. 
The phosphorylation of MYOM2 S76 disrupts the binding of MYOM2, and LMM [43] and is more 
prevalent after exercise in the morning compared to evening. Myosin binding protein C (MYBPC1) 
localizes to the M-band through its interaction with obscurin [44]. MYBPC1 is required for the binding 
of muscle creatine kinase (KCRM) to the M-band region. MYBC1 exhibits differences in post-
translational state between morning and evening, which are likely to be phosphorylation [45]. KCRM 
S24 phosphorylation is greater in the morning than evening. The N-terminal region of KCRM is 
necessary for the creatine/phosphocreatine- and pH-dependent interaction of KCRM with the M-band 
[46]. 
The M-band is a key component of the sarcomeric structure that distributes force across 
opposing myosin thick filaments [38] and is well-placed to mediate mechanical signals to the nucleus 
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protein interactions redrawn from [38]. Myomesin 1 (MYOM1) and obscurin (OBSCN) are principal
M-band proteins [39]. The N-terminal regions of MYOM1 interact with myosin heavy chain (MYH),
titin (TTN), and muscle creatine kinase (KCRM), whereas the C-terminal regions of MYOM1 dimerize
in an anti-parallel arrangement that corresponds with the M-bridges [40]. MYOM1 interacts with
the C-terminal regions of TTN within the M-band. The TTN kinase domain (resides 32,178–32,432)
includes the regulatory Y32341 residue [41], whereas we discovered that the phosphorylation of S33624 of
TTN is greater in the morning than evening. Myomesin 2 (MYOM2, formally known as M-Protein)
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interacts with the light meromyosin (LMM) region of MYH and the C-terminal region of TTN [42].
The phosphorylation of MYOM2 S76 disrupts the binding of MYOM2, and LMM [43] and is more
prevalent after exercise in the morning compared to evening. Myosin binding protein C (MYBPC1)
localizes to the M-band through its interaction with obscurin [44]. MYBPC1 is required for the binding of
muscle creatine kinase (KCRM) to the M-band region. MYBC1 exhibits differences in post-translational
state between morning and evening, which are likely to be phosphorylation [45]. KCRM S24
phosphorylation is greater in the morning than evening. The N-terminal region of KCRM is necessary
for the creatine/phosphocreatine- and pH-dependent interaction of KCRM with the M-band [46].
The M-band is a key component of the sarcomeric structure that distributes force across opposing
myosin thick filaments [38] and is well-placed to mediate mechanical signals to the nucleus and wider
muscle proteome. MYOM2, formerly known as 165 kDa M-protein, is a major component of
the M-Band and is specifically expressed in cardiac and fast-twitch skeletal muscle [47]. MYOM2 binds to
the light meromyosin (LMM) tail of myosin heavy chains in the M-band region and the phosphorylation
of MYOM2 S76 by protein kinase A (PKA) disrupts the binding of MYOM2 and LMM in vitro [43].
We report a significantly greater phosphorylation of MYOM2 S76 in the morning, which could indicate
alteration to the M-band structure and the disruption of force transmission in vivo. The circadian
regulation of this effect is supported by data from animals carrying clock gene mutations that
exhibit a decrement in myofiber-specific force and disruption to the hexagonal structure of thick
filament proteins [17]. In the future it will be of interest to investigate whether differences in protein
phosphorylation also exist between the muscle of wild-type and clock mutant mice.
We report that the phosphorylation of TTN S33624 near the C-terminus of titin is greater in
the morning than evening in human muscle. The kinase domain of human titin includes Y32341 [41].
The TTN S33624 site reported here has been previously detected in phosphoproteome maps of human
skeletal muscle [26], but as of yet, no function is assigned to S33624 phosphorylation. Titin is involved
in sensing mechanical strain via its C-terminal kinase domain located at the sarcomeric M-band [48].
Mechanical strain causes unfolding of the kinase domain, which occurs prior to unfolding of the structural
titin Ig/Fn domains. The kinase domain of titin is involved in gene expression of muscle E3 ligases
in response to mechanical strain [49]. If TTN S33624 phosphorylation alters the stretch responsiveness
of titin kinase, this could raise questions regarding potential responsiveness to training in morning
versus evening.
Contrary to our expectation, in-depth analysis of myosin light chain proteoforms found no
differences between morning and evening conditions (Table 1). In skeletal muscle, the phosphorylation
of myosin regulatory light chain (MLRS) contributes to twitch potentiation in fast-twitch fibers [20].
However, we report that the post-translational modification of neither essential nor regulatory myosin
light chain isoforms is associated with diurnal differences in maximum isometric force in human
muscle. Further analysis of myofibrillar proteoforms using broader range (pH 3–10) isoelectric focusing
(Figure 4) discovered putative post-translational modifications of myofibrillar proteins and metabolic
enzymes in human muscle (Table 2) that raise new hypotheses regarding the differences in muscle
force output. MYBPC1 is of interest because it is a major component of the muscle thick filament [50].
Proteomic analysis of hearts from wild-type and cardiac clock mutant mice [45] reported circadian
differences in the level of phosphorylation of MYBPC1 using the phosphor-specific, Pro-Q diamond,
stain. The phosphorylation of MYBPC1 is associated with enhanced contractility in response to
beta-adrenergic receptor stimulation [51], and MYBPC1 can be phosphorylated at numerous sites
by protein kinase A (PKA) and protein kinase C [52]. We were unable to unambiguously identify
the site-specific modification of MYBPC1 that differed in human muscle between the morning
and evening conditions. Nevertheless, the consistency in findings between the heart [45] and human
skeletal (current work) muscle indicate that further targeted analysis on MYBPC1 proteoforms
is warranted.
Muscle creatine kinase (KCRM, previously known as MM-CK) is a prominent M-band protein
and key enzyme in high-energy phosphate metabolism [53]. MYBPC1 is necessary for the recruitment
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of KCRM to myosin, and this interaction is dependent on both the ratio of creatine/phosphocreatine
and intracellular pH [53]. The interaction between KCRM and the M-band weakens as the intracellular
pH rises and the ratio of creatine/phosphocreatine increases [53]. KCRM also interacts with
immunoglobulin-like domains near the C-terminal of myomesin and M-protein (MYOM2; [46]).
The site (S24) of KCRM phosphorylation reported here (Figure 5) is immediately adjacent to K25, which
is one of 4 lysine residues near the N-terminus of KCRM that are required for the pH-dependent
interaction between KCRM and M-band proteins [46]. The phosphorylation of KCRM S24 has been
previously detected in phosphoproteome maps of human muscle [26], but the upstream kinase
and functional consequences of KCRM S24 phosphorylation remain to be elucidated. Based on our
current findings, it may be hypothesized that KCRM S24 phosphorylation has a disruptive influence
and may weaken the interaction between KCRM and the M-band region.
In addition to sarcomeric proteins, isoforms of heat shock protein 90 (HSP90) and the mitochondrial
import receptor protein (TOM70) also exhibited a diurnal difference in phosphorylation status.
HSP90 does not localize to the M-band, but it is required for the chaperone-mediated assembly of
myosin in muscle [54]. HSP90 modulates the myosin replacement rate into myofilaments and influences
the expression of myosin genes [55]. Post-translational modifications, including the phosphorylation,
of HSP90 are recognized to modulate its chaperone activity [56], but an in-depth understanding of
the effects of different site-specific modifications is not yet available. The phosphorylation of S226
and S255 of HS90B and S231 HS90A reported here (Figure 5) is mediated by casein kinase 2 (CK2), which
is known to modulate the molecular clock through the phosphorylation of Period 2 S53 [57]. TOM70 S91
is reported to exhibit a circadian rhythm in mouse liver [58], and the deletion of BMAL1 causes muscle
mitochondrial dysfunction [17]. The phosphorylation of TOM70 S174 by PKA inhibits its receptor
activity [59], but the effect of S91 phosphorylation, reported here, remains to be determined. The future
phosphoproteomic analysis of mitochondria may give further insight to time-of-day differences in
the response of muscle metabolism to exercise [16].
Findings from our non-targeted analysis of protein phosphorylation suggest a connection to
PKA. Several of the phosphorylation sites on myofibrillar proteins have been reported to be targets of
PKA, and we detected greater phosphorylation of the catalytic subunit of PKA on threonine (T)198
in morning samples. PKA is a key second messenger of muscle beta-adrenergic receptor signaling,
and adrenal hormones, including catecholamines and glucocorticoids, have a role in synchronizing
circadian rhythms across peripheral tissues in vivo [60]. Glucocorticoids are regarded as the main
synchronizing hormones [61], but the circadian control of liver metabolism in mice [62] has been linked
with adrenergic receptor signaling. The acrophase (approximately mid-day) in plasma catecholamines
in humans [63] does not coincide with the morning–evening differences in muscle isometric force.
However, plasma catecholamine response to exercise is greater in the morning than evening [63].
There is a well-established interaction between glucocorticoids and adrenergic receptor signaling [64],
and the early morning peak in cortisol could potentiate responses to adrenaline (consistent with our
data). Glucocorticoid stimulation may enhance the intracellular 3’,5’-cyclic adenosine monophosphate
(cAMP) response to beta-adrenergic receptor stimulation, but this might be expected to result in greater
muscle force output [65] in the morning. The acrophase of plasma cortisol early in the morning
coincides with the bathyphase of muscle force production. The phosphorylation of PKA T198 is
mediated by phosphatidylinositol 3-kinase [66], which opens the possibility of upstream regulation by
interaction between the glucocorticoid receptor and p85α subunit of phosphatidylinositol 3-kinase [67].
Our data provide the basis for investigating the role of glucocorticoids in the regulation of cAMP in
the context of time-of-day differences in muscle force.
The primary aim of this study was to investigate whether modifications occur to the contractile
proteins of skeletal muscle that associate with its ability to generate force at the two different times
of day. Biopsies were performed to investigate whether modifications co-occur to the contractile
proteins of skeletal muscle that affect its ability to produce force at each time of day. A limitation
of our work is that baseline samples were not collected prior to exercise, so it remains to be shown
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whether the time-of-day differences in protein post-translational modification exist in muscle that has
not performed exercise. Overall, the phosphorylation of muscle proteins was greater after exercise
in the morning than in the evening, which may indicate a diurnal difference in muscle protein
phosphatase activity. The modulation of protein phosphatase 1 activity alters circadian rhythms in
flies [68], but the selective dephosphorylation of proteins in human muscle remains to be investigated.
We principally studied phosphorylation, but other post-translational modifications may also be
important. The majority of covalent protein modifications change the isoelectric point of proteins,
which makes 2DGE an elegant tool for the non-targeted discovery of protein modifications. However,
the relatively small samples extracted from 2DGE spots, particularly in human biopsy samples where
the starting material is also limited, make this work challenging. A third limitation concerning our
study was the selection of participants for biopsies; in our case, we biopsied only those who were
happy to give consent. Even though significant diurnal differences were found in expected parameters,
future work should establish diurnal variation first within the population who have consented to have
biopsies and select those participants who have the greatest variation.
5. Conclusions
Exercise in the morning, compared to the evening, resulted in the greater phosphorylation
of proteins in human muscle that are components of or are associated with the M-band region.
The phosphorylation of these proteins may alter the M-band structure and disrupt force transmission,
thus potentially explaining the lower force output in the morning compared to evening. Our findings
in humans add to data from animal models where deletion of the clock protein, BMAL1, results in
disorganization of the 3D myofibrillar lattice and a loss in muscle force. The data generated in human
muscle provide new targets to investigate the modulation of muscle force output or the application of
exercise as a Zeitgeber of muscle function.
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